Table 6.
Log-rank test for univariate analysis.
| Factor | 3-year LRFS | 3-year NRFS | 3-year DMFS | 3-year OS | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age (y) | ||||||||||||
| ≤50 | 94.8% | χ 2 = 4.046 | P = 0.044 | 94.8% | χ 2 = 1.211 | P = 0.271 | 91.5% | χ 2 = 6.063 | P = 0.014 | 83.1% | χ 2 = 6.791 | P = 0.009 |
| >50 | 80.8% | 100.0% | 70.4% | 58.8% | ||||||||
| Gender | ||||||||||||
| Male | 93.7% | χ 2 = 2.848 | P = 0.091 | 96.8% | χ 2 = 0.202 | P = 0.653 | 82.1% | χ 2 = 1.815 | P = 0.178 | 74.0% | χ 2 = 0.135 | P = 0.713 |
| Female | 81.0% | 94.4% | 94.7% | 77.3% | ||||||||
| T Stage | ||||||||||||
| T1 | 88.9% | χ 2 = 7.424 | P = 0.060 | 100.0% | χ 2 = 11.293 | P = 0.010 | 89.5% | χ 2 = 1.357 | P = 0.716 | 81.0% | χ 2 = 10.218 | P = 0.017 |
| T2 | 97.7% | 100.0% | 87.0% | 85.1% | ||||||||
| T3 | 80.0% | 80.0% | 77.8% | 53.8% | ||||||||
| T4 | 70.5% | 90.9% | 75.0% | 55.6% | ||||||||
| N Stage | ||||||||||||
| N0 | 85.7% | χ 2 = 1287 | P = 0.732 | 100.0% | χ 2 = 6.116 | P = 0.160 | 100.0% | χ 2 = 8.160 | P = 0.043 | 85.7% | χ 2 = 1.765 | P = 0.622 |
| N1 | 90.0% | 100.0% | 72.7% | 70.3% | ||||||||
| N2 | 92.6% | 92.9% | 86.2% | 73.5% | ||||||||
| N3 | 100.0% | 83.3% | 100.0% | 71.4% | ||||||||
| Node category | ||||||||||||
| N+ | 85.7% | χ 2 = 0.722 | P = 0.395 | 100.0% | χ 2 = 0.871 | P = 0.351 | 100.0% | χ 2 = 3.782 | P = 0.052 | 85.7% | χ 2 = 1.700 | P = 0.192 |
| N− | 92.1% | 95.2% | 80.9% | 71.8% | ||||||||
| UICC Stage | ||||||||||||
| I | 83.3% | χ 2 = 6.097 | P = 0.107 | 100.0% | χ 2 = 3.235 | P = 0.357 | 100.0% | χ 2 = 1.634 | P = 0.652 | 82.5% | χ 2 = 3.645 | P = 0.302 |
| II | 100.0% | 100.0% | 82.1% | 85.0% | ||||||||
| III | 86.7% | 93.1% | 83.3% | 96.4% | ||||||||
| IV | 80.0% | 90.9% | 91.7% | 66.7% | ||||||||
| IGRT and GTVnx to pGTVnx margin | ||||||||||||
| Every day and 5 mm | 92.5% | χ 2 = 1.098 | P = 0.295 | 100% | χ 2 = 1.096 | P = 0.295 | 86.8% | χ 2 = 1.409 | P = 0.306 | 81.1% | χ 2 = 0.299 | P = 0.585 |
| Every week and 3 mm | 96.8% | 97.9% | 93.7% | 86.3% | ||||||||
| Chemotherapy was performed or not in stage III-IV patients | ||||||||||||
| No | 57.1% | χ 2 = 4.563 | P = 0.033 | 100.0% | χ 2 = 0.406 | P = 0.524 | 57.1% | χ 2 = 4.563 | P = 0.033 | 55.6% | χ 2 = 0.648 | P = 0.421 |
| Yes | 90.0% | 92.1% | 90.0% | 71.7% | ||||||||
| Concurrent chemotherapy was performed or not in stage III-IV patients | ||||||||||||
| No | 81.5% | χ 2 = 0.577 | P = 0.447 | 91.7% | χ 2 = 0.150 | P = 0.699 | 81.5% | χ 2 = 0.577 | P = 0.447 | 70.0% | χ 2 = 0.047 | P = 0.829 |
| Yes | 90.0% | 94.7% | 90.0% | 68.0% | ||||||||
| Anti-EGFR monoclonal antibody was used or not in stage III-IV patients | ||||||||||||
| No | 84.0% | χ 2 = 0.071 | P = 0.789 | 91.3% | χ 2 = 0.219 | P = 0.640 | 84.0% | χ 2 = 0.071 | P = 0.789 | 65.6% | χ 2 = 0.399 | P = 0.528 |
| Yes | 86.4% | 95.0% | 86.4% | 73.9% | ||||||||